AMP partners focus on four diseases—Alzheimer's disease, type 2 diabetes mellitus, rheumatoid arthritis, and systemic lupus erythematosus--and share genomic and molecular data to accelerate research into disease treatment.
All AMP partners have agreed to make the AMP data and analyzes publicly accessible to the broad biomedical community through an online portal. AMP governs their projects through steering committees for each of the three disease areas, with representation from all partners. The steering committees are managed by the Foundation of the National Institute of Health (FNIH) under the direction of an AMP Executive Committee comprised of representatives from NIH, participating industry leaders, FDA, and non-profit organizations.
The AMP initiative combines public-private expertise and pooled data to reduce the time and cost of developing biomarkers for disease treatment. The project attempts to overcome fragmentation in the pharmaceutical industry and improve innovation in drug therapy. By combining data, the AMP portal can find new drug targets, and reduce wasteful repetition of testing found when companies work in-silo.